Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer

Cancer Science

Volumn 104, Issue 3, 2013, Pages 282-290

  Tanemura, Masahiro ^a,b   Miyoshi, Eiji ^b   Nagano, Hiroaki ^b   Eguchi, Hidetoshi ^b   Taniyama, Kiyomi ^a   Kamiike, Wataru ^a   Mori, Masaki ^b   Doki, Yuichiro ^b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GAL PROTEIN; CARCINOEMBRYONIC ANTIGEN; CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAL ANTIBODY; HERMES ANTIGEN; K RAS PROTEIN; MESOTHELIN; MUCIN 1; PROTEIN ANTIBODY; PROTEIN P53; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; APE; CANCER EPIDEMIOLOGY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STEM CELL; CELL EXPANSION; CERCOPITHECIDAE; COLORECTAL CANCER; CYTOLYSIS; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOGENICITY; LIVER CELL CARCINOMA; MALIGNANT MESOTHELIOMA; MARSUPIAL; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PLACENTAL MAMMALS; PLATYRRHINI; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; STOMACH CANCER; XENOTRANSPLANTATION;

ANTIGEN-ANTIBODY REACTIONS; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; CANCER VACCINES; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; T-LYMPHOCYTES; TRISACCHARIDES;

EID: 84874458512     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12084     Document Type: Review

References (51)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2011; 61: 133-4.
2. Lepisto AJ, Moser AJ, Zeh H et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008; 6: 955-64.
3. Galili U. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol 2005; 83: 674-86.
4. Macher BA, Galili U. The Galalpha1, 3Galbeta1, 4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 2008; 1780: 75-88.
5. Galili U, Wigglesworth K, Abdel-Motal UM. Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J Immunol 2007; 178: 4676-87.
6. Abdel-Motal UM, Wigglesworth K, Galili U. Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol Immunother 2009; 58: 1545-56.
7. Abdel-Motal UM, Wigglesworth K, Galili U. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine 2009; 27: 3072-82.
8. Rossi GR, Mautino MR, Unfer RC et al. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha (1, 3)-galactosyl epitopes. Cancer Res 2005; 65: 10555-61.
9. Rossi GR, Unfer RC, Seregina T, Link CJ. Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha (1, 3) galactosyl epitopes. Cancer Immunol Immunother 2005; 54: 999-1009.
10. Eto T, Ichikawa Y, Nishimura K, Ando S, Yamakawa T. Chemistry of lipid of the posthemyolytic residue or stroma of erythrocytes. XVI. Occurrence of ceramide pentasaccharide in the membrane of erythrocytes and reticulocytes of rabbit. J Biochem 1968; 64: 205-13.
11. Stellner K, Saito H, Hakomori SI. Determination of aminosugar linkages in glycolipids by methylation. Aminosugar linkages of ceramide pentasaccharides of rabbit erythrocytes and of Forssman antigen. Arch Biochem Biophys 1973; 155: 464-72.
12. Wood C, Kabat EA, Murphy LA, Goldstein IJ. Immunochemical studies of the combining sites of the two isolectins, A4 and B4, isolated from Bandeiraea simplicifolia. Arch Biochem Biophys 1979; 198: 1-11.
13. Joziasse DH, Shaper JH, Jabs EW, Shaper NL. Characterization of an alpha 1-3-galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene. J Biol Chem 1991; 266: 6991-8.
14. Lantéri M, Giordanengo V, Vidal F, Gaudray P, Lefebvre JC. A complete alpha1, 3-galactosyltransferase gene is present in the human genome and partially transcribed. Glycobiology 2002; 12: 785-92.
15. Tisato V, Cozzi E. Xenotransplantation: an overview of the field. Methods Mol Biol 2012; 885: 1-16.
16. Ekser B, Ezzelarab M, Hara H et al. Clinical xenotransplantation: the next medical revolution? Lancet 2012; 379: 672-83.
17. Sandrin MS, Fodor WL, Mouhtouris E et al. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1995; 1: 1261-7.
18. Tanemura M, Miyagawa S, Koyota S et al. Reduction of the major swine xenoantigen, the alpha-galactosyl epitope by transfection of the alpha2, 3-sialyltransferase gene. J Biol Chem 1998; 273: 16421-5.
19. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006; 17: 403-9.
20. Garcea G, Dennison AR, Pattenden CJ et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008; 9: 99-132.
21. Roy R, Maraveyas A. Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist 2010; 15: 259-69.
22. Kosuge T, Sakamoto Y, Ueno H. Postoperative adjuvant therapy. J Hepatobiliary Pancreat Sci 2011; 18: 792-96.
23. Mackenzie RP, McCollum AD. Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev Anticancer Ther 2009; 9: 1473-85.
24. Wedén S, Klemp M, Gladhaug IP et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011; 128: 1120-8.
25. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 2003; 10: 972-92.
26. Weighardt H, Heidecke CD, Emmanuilidis K et al. Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production. Surgery 2000; 127: 309-15.
27. Saito H, Dubsky P, Dantin C et al. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res 2006; 8: R65.
28. Thomas AM, Santarsiero LM, Lutz ER et al. Mesothelin-specific CD8 (+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004; 200: 297-306.
29. Jaffee EM, Hruban RH, Biedrzycki B et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145-56.
30. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44: 46-53.
31. Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009; 229: 41-66.
32. Ermann J, Fathman CG. Costimulatory signals controlling regulatory T cells. Proc Natl Acad Sci U S A 2003; 100: 15292-3.
33. Bear AS, Cruz CR, Foster AE. T cells as vehicles for cancer vaccination. J Biomed Biotechnol 2011; 2011: 417403.
34. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012; 11: 311-31.
35. Kohrt HE, Houot R, Marabelle A et al. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012; 4: 511-27.
36. Deguchi T, Tanemura M, Miyoshi E et al. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer. Cancer Res 2010; 70: 5259-69.
37. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6: 339-53.
38. Schuman JT, Grinstead JS, Apostolopoulos V, Campbell AP. Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen. Biopolymers 2005; 77: 107-20.
39. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3: 630-41.
40. Loveland BE, Zhao A, White S et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006; 12: 869-77.
41. Wang Z, Li Y, Ahmad A et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011; 8: 27-33.
42. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
43. MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 2004; 5: 541-9.
44. Kawakami Y, Fujita T, Matsuzaki Y et al. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 2004; 95: 784-91.
45. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol 2008; 26: 2806-12.
46. Livingston P. The unfulfilled promise of melanoma vaccines. Clin Cancer Res 2001; 7: 1837-8.
47. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999-1005.
48. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
49. Campbell PJ, Yachida S, Mudie LJ et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-13.
50. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-7.
51. Segal NH, Parsons DW, Peggs KS et al. Epitope landscape in breast and colorectal cancer. Cancer Res 2008; 68: 889-92.